Management of Italian Patients With Advanced Non–Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study

Micro-Abstract After second-line therapy, patients with advanced non–small-cell lung cancer (NSCLC) might receive further treatment. The primary aim of the longitudinal phase of the LIFE (non–small-cell Lung cancer management In patients progressing after First linE of treatment in the metastatic setting) study was to describe the portion of patients who, after second-line treatment according to clinical practice, received third-line therapy outside of a clinical trial. This portion was not negligible: third-line chemotherapy or erlotinib was administered to 158 patients (40.4%).